74,000 Sign FARA Petition Asking FDA, Reata to Move Ahead on Omav

74,000 Sign FARA Petition Asking FDA, Reata to Move Ahead on Omav

287074

74,000 Sign FARA Petition Asking FDA, Reata to Move Ahead on Omav

Over about two weeks, more than 74,000 people worldwide have signed a petition from the Friedrich’s Ataxia Research Alliance (FARA) requesting that omaveloxolone (omav) be made available to people with Friedrich’s ataxia (FA) as quickly as possible. The petition specifically asks Reata Pharmaceuticals to submit a new drug application (NDA) for omaveloxolone to the U.S. Food and Drug Administration (FDA) on an urgent basis, and that the regulatory agency consider its approval based on existing evidence. This “call…

You must be logged in to read/download the full post.